Ian Sanderson
About Ian Sanderson
Ian Sanderson serves as the Chief Financial Officer at Nimbus Therapeutics, bringing extensive experience in equity research and venture capital within the pharmaceuticals industry. He has held various leadership roles, including CFO positions at Boston Pharmaceuticals and Catabasis Pharmaceuticals, and has a strong background in structuring partnerships for innovative medicine development.
Current Role at Nimbus Therapeutics
Ian Sanderson serves as the Chief Financial Officer at Nimbus Therapeutics, a position he has held since 2021. In this role, he is responsible for overseeing the financial operations of the company, which focuses on developing breakthrough medicines through innovative approaches. His expertise in structuring partnerships enhances the company's ability to deliver effective treatments.
Previous Experience in Pharmaceuticals
Ian Sanderson has extensive experience in the pharmaceuticals industry. He was the Chief Financial Officer at Boston Pharmaceuticals from 2016 to 2021, where he managed financial strategies and operations. Prior to that, he served as CFO at Catabasis Pharmaceuticals from 2013 to 2016, contributing to financial planning and investment strategies. His role as Senior Advisor at JSB-Partners, LP from 2012 to 2013 further solidified his expertise in the sector.
Education and Expertise
Ian Sanderson holds a Bachelor of Arts in Political Economy from Williams College, where he studied from 1979 to 1983. He later earned a Master of Business Administration from The Wharton School, completing his studies from 1987 to 1989. His educational background supports his strong expertise in equity research, venture capital, and financial management within the pharmaceuticals industry.
Career Background in Finance
Before his roles in the pharmaceuticals sector, Ian Sanderson gained significant experience in finance. He worked as Managing Director of Institutional Research at Cowen and Company for 20 years, from 1992 to 2012, focusing on equity research. He also held positions as Senior Associate at Houlihan Lokey from 1989 to 1992 and as an Associate at Cambridge Associates from 1985 to 1987, building a robust foundation in financial analysis and investment.
Skills in Drug Development
Ian Sanderson possesses skills in designing potent and selective small molecule compounds that target challenging proteins involved in human diseases. His expertise in structuring synergistic partnerships is instrumental in advancing the development of breakthrough medicines, aligning with the goals of Nimbus Therapeutics.